This document describes the development of monoclonal antibodies that target the DSVVYG peptide sequence of human osteopontin. Several antibody clones were selected and tested in ELISA and cell adhesion assays. Six antibody clones emerged as most promising based on their ability to detect recombinant and native osteopontin in ELISA and influence breast cancer cell adhesion. Further analysis is planned using these six clones, including western blotting of native osteopontin and additional cell adhesion assays using native osteopontin to better understand post-translational modifications.